Nachrichten zur ACADIA Pharmaceuticals Aktie

Omnicom (OMC) Q1 2026 Earnings Transcript

Image source: The Motley Fool.DATETuesday, April 28, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChairman and Chief Executive Officer — John WrenExecutive…

Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to Buy from Neutral, arguing that a recent pullback in the stock has…

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do…

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

…

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today…

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

…

Acadia Pharmaceuticals stock rises on Mizuho upgrade By Investing.com

Acadia Pharmaceuticals stock rises on Mizuho upgrade…

ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug By Investing.com

ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug…

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today…

Heres Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Heres Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals,” the “Company”), a…

Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com

Acadia Pharmaceuticals director Daly sells $670k in stock…

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Hims & Hers Health (NYSE:HIMS), ACADIA Pharmaceuticals (NASDAQ:ACAD)

…

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx…

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and…

Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold

…

Ionis Pharmaceuticals Aktienanalyse: Tryngolza und Dawnzera starten durch - Raymond James passt Kursziel an!

Bad Marienberg (www.aktiencheck.de)???? Ionis Pharmaceuticals begeistert Analysten: Raymond James hebt Kursziel auf 75 USD - "strong buy"Ionis Pharmaceuticals Inc. (ISIN:…

Kaufalarm bei Acadia Pharmaceuticals (ACAD): Innovationsführer in der Neurotherapie mit starkem Wachstumspotenzial!

Acadia Pharmaceuticals (ACAD) widmet sich insbesondere der Behandlung von Parkinson-Psychose, dem Rett-Syndrom und der Alzheimer-Psychose. Die Parkinson-Psychose (PDP) betrifft etwa…

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

…

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

…

Acadia Pharmaceuticals shares surge on patent ruling By Investing.com

Acadia Pharmaceuticals shares surge on patent ruling…

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the…

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

…

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…

BioStock: Saniona strengthened its cash position and advanced through partnership

Saniona’s key milestone in 2024 was securing an exclusive worldwide licensing agreement with Acadia Pharmaceuticals worth up to USD 610…

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the…

BioStock: Saniona’s CEO responds to investors’ questions

Saniona’s collaboration with Acadia Pharmaceuticals, signed in November, marked a significant milestone for the company. With a total potential value…